Amyris, Inc. has sold its vitamin E royalty agreement to Koninklijke DSM NV (Royal DSM). The move assigns Amyris’s rights to vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million during the next three years. ...